Starpharma announced it has completed its Share Purchase Plan (SPP) having raised approximately $1.9 million. Combining the SPP with the recent institutional placement which raised $32 million (before costs); the Company has successfully raised a total of approximately $34 million at $0.73 per share.

"Starpharma has signed a memorandum of understanding with a Chinese company to make and sell its VivaGel-coated condom in China...The Chinese company is a major supplier of condoms to the Chinese government's Birth Control Department and Disease Prevention Department. The so-called government market in China requires about three billion condoms each year for birth control and disease prevention."

Go to the article (external link)

Starpharma is pleased to attach documentation regarding its Share Purchase Plan (SPP).

Starpharma announced today that it has signed a Memorandum of Understanding (MOU) with a Chinese company who is a major provider of condoms to the Chinese government.  The MOU outlines the key commercial and other terms for Starpharma’s partner to manufacture and sell a VivaGel^® coated condom to the Government segment of the Chinese market.

Starpharma is pleased to announce it has raised A$32 million via a placement to domestic and international institutional, sophisticated and professional investors (“Placement”). Eligible shareholders will also have the opportunity to participate, at the same price, through a Share Purchase Plan (SPP) which will raise up to a further A$3 million.

Starpharma today announced that AstraZeneca has selected a second DEP™ candidate and Starpharma will now commence a new DEP™ project incorporating the second proprietary AstraZeneca oncology molecule.

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 2.00pm today.

Download: AGM - Chair address and CEO presentation (pdf file, 1MB)

The Australian's Sarah-Jane Tasker reports that "Starpharma's shares have hit a fresh high following positive results in a preclinical trail for its ovarian cancer model. The company said a cancer drug treatment coupled with its dendrimer (DEP) technology - which allows for more effective drug delivery - had resulted in complete tumour regression and 100 per cent survival in a preclinical trial done on mice."

Go to the artice (external link)

Melbourne, Australia; Starpharma today announced that treatment with its novel antibody-targeted DEP^® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model.

Starpharma today announced it has received the anticipated $3.4M of R&D tax incentive refund related to FY15 expenditures.